

A detailed 3D illustration of a cell. The cell membrane is shown in light grey with various receptors and channels. Inside, the nucleus is visible with a red nucleolus and yellow DNA strands. A green protein complex is bound to the DNA. The cytoplasm contains various organelles and smaller protein structures. The overall scene is brightly lit, giving it a clean, scientific appearance.

# Acuitas Therapeutics

Non-Confidential Presentation

# Overview

## WHO WE ARE

Acuitas is a globally recognized biotechnology company specializing in the **development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP).**

Our LNP have currently enable two commercial products:

**onpattro**  
(patisiran)  
lipid complex injection  
10 mg/5 mL

**COMIRNATY**  
(COVID-19 Vaccine, mRNA)

## WHO WE WORK WITH

We work with a variety of organizations, including:



Cutting edge **pharmaceutical & biotechnology** companies



Leading **academics in universities & institutes**



**Foundations & NGOs**

## HOW WE WORK

As a technology platform provider, we exclusively work in collaboration with partners.

We do not have our own drug development programs – **we are focused on supporting our partners to bring their drug products to patients.**



# Applying Our LNP Technology

## Gene Modulation

Expression of an **epigenetic editor** to modify gene expression **without changing the genetic code**.

## Antibodies

Expression of **prophylactic or therapeutic antibodies** to treat current and emerging diseases.

## Gene Editing

Expression of a **genome editing** protein to modify gene expression.

## Vaccines

Expression of viral or bacterial proteins to generate a protective **immune response**.

Expression of **tumour antigens** (including personalized cancer vaccines).

## Therapeutic Protein Delivery

Expression of a **human protein** to treat disease.



# Our Partners' Success

## Commercial Products

 Alnylam<sup>®</sup>

 onpattro<sup>®</sup>  
(patisiran) lipid complex injection  
10 mg/5 mL

First Clinically Approved  
**RNA interference-based  
Medicine**

 Pfizer

 BIONTECH

 COMIRNATY<sup>®</sup>  
(COVID-19 Vaccine, mRNA)

First Clinically Approved  
**mRNA-based Medicine**

First Widely Approved  
**COVID-19 Vaccine**


## Products in the Clinic

**17** in Phase 1

**4** in Phase 2


**2** in Phase 3

# Our Approach to Innovation




# Our Approach to Innovation

## Improved Lipids for Gene Editing/Gene Modulation Applications (IV)




Enhanced potency enables partner programs across a broad range of therapeutic applications

## Improved Lipids for Vaccine Applications (IM)



# Accelerating Clinical Entry



**Our breadth and depth of capabilities enables end-to-end drug development support.**

# Why Acuitas?

## 1 **Best-in-class and First-in-class**

We have unparalleled technology with:

- **First-in-class and best-in-class** drug products commercialized, including Onpattro® and Comirnaty®.
- A broad and **comprehensive IP portfolio.**

## 2 **Accelerated Clinical Entry**

We understand the importance of early clinical entry.

We provide access to **cGMP-grade lipids.**

Our **expertise in tech transfer and product scale up** de-risks your development program, saving you time and money.

Our partners have initiated **26 clinical trials** in the last 2 years.

## 3 **Unparalleled Scientific Leadership & Experience**

Working with academic scientists and key opinion leaders we **publish regularly in the top scientific journals.**

Our team is at the cutting edge of scientific discovery.



# Our Scientific Leadership

## Mechanism of Action

nature  
nature

- Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals (2023)
- Molecular fate-mapping of serum antibody responses to repeat immunization (2023)

## Therapeutic Areas

Cell

Cell

- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals (2024)
- Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system (2024)

## Vaccine Improvements

Science

nature

Cell

- A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection
- Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus (2024)
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction (2024)

## Extra-hepatic Application

Cell

ADVANCED HEALTHCARE  
MATERIALS


Science

Science


- Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke (2024)
- Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions (2024)
- In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles delivering mRNA (2023)
- CAR T cells produced in vivo to treat cardiac injury (2022)

For a current list of publications, please visit our website [here](#).

# Our Business Development Process



\*: Shipping costs may apply.



[bd@acuitastx.com](mailto:bd@acuitastx.com)  
<https://acuitastx.com/>